Urteste publishes first peer-reviewed paper on Panuri pancreatic cancer test

Urteste said July 22 that Diagnostics published the first peer-reviewed paper on its Panuri urine test for pancreatic cancer, marking a milestone as the investigational device continues multicenter clinical testing in Europe. The company plans to discuss the program at ADLM 2026 in Anaheim later this month.

Why it matters: - The publication gives Urteste peer-reviewed validation for the analytical work behind Panuri, its urine-based pancreatic cancer test. - Panuri is aimed at earlier detection of pancreatic ductal adenocarcinoma, which is often diagnosed late and is one of the deadliest cancers. - The result supports Urteste's push toward European regulatory clearance and future commercialization.

What happened: - Urteste S.A. announced the publication of its first peer-reviewed scientific article on Panuri on July 22, 2026. - Diagnostics published the paper, titled "Development and Analytical Evaluation of Urine-Based Test for Detection of Pancreatic Cancer." - Urteste is based in Gdansk, Poland and trades on the Warsaw Stock Exchange under the ticker URT. - The Panuri test is still investigational and has not received CE marking.

The details: - Panuri is an in vitro diagnostic device under development for pancreatic cancer. - The test measures disease-associated proteolytic activity in urine using proprietary synthetic peptides. - The analytical development showed 89% analytical sensitivity, with a 95% confidence interval of 78.5% to 94.9%. - The assay showed 75% analytical specificity, with a 95% confidence interval of 64.8% to 83.5%. - Urteste reported high analytical precision, including repeatability, within-laboratory precision and inter-laboratory reproducibility, with coefficients of variation below 10%. - The paper describes the analytical validation performed during assay development. - The article is available in Diagnostics via the published paper. - Urteste has 13 prototypes of diagnostic tests across cancers of the breast, brain, stomach, bile ducts, ovaries, bladder, endometrium, kidneys, colon, lungs, liver, pancreas and prostate. - Urteste says those cancer types account for nearly 70% of cancer-related deaths worldwide.

Between the lines: - The paper adds scientific credibility, but the key question remains whether the analytical results translate into strong clinical performance in patients. - Urteste is positioning Panuri as a non-invasive and affordable screening-support tool, which would matter if the company can clear European regulatory hurdles. - The company is using the publication and upcoming conference presence to build visibility with potential partners and customers.

What's next: - Urteste is running a prospective multicenter clinical performance study for Panuri in patients being evaluated for suspected pancreatic cancer. - The study spans 30 clinical sites in Poland, Italy and Hungary. - The trial is expected to include about 550 evaluable participants. - The study results are intended to support the European regulatory process under the In Vitro Diagnostic Medical Devices Regulation. - Members of Urteste's management board will attend ADLM 2026 in Anaheim, California, from July 26-30, 2026. - Urteste plans to present Panuri progress, discuss the publication and clinical study, and meet potential strategic and commercial partners at the event.

The bottom line: - Urteste has moved Panuri from lab validation to peer-reviewed visibility, but the test still needs clinical and regulatory proof before it can reach the market.